Real-life analysis of immunotherapy as the second or later lines treatment in patients with metastatic non-small cell lung cancer
Göster/ Aç
Erişim
info:eu-repo/semantics/embargoedAccessTarih
2021Yazar
Aydın, S. G.Kutlu, Yasin
Açıkgöz, Özgür
Bilici, A.
Hamdard, Jamshid
Ölmez, Ömer Fatih
Yıldız, Özcan
Üst veri
Tüm öğe kaydını gösterKünye
Aydın, S. G., Kutlu, Y., Açıkgöz, Ö., Bilici, A., Hamdard, J., Ölmez, Ö. F. ... Yıldız, Ö. (2021). Real-life analysis of immunotherapy as the second or later lines treatment in patients with metastatic non-small cell lung cancer. Journal of Thoracic Oncology içinde (S1078-S1079. ss.).Özet
Introduction: Non-small cell lung cancer (NSCLC) accounts for the majority of lung cancer and in the absence of driver mutation preferred treatment is incorporation of immunotherapy.But for patients treated with chemotherapy alone,in second line setting atezolizumab or nivolumab are appropriate option regardless of PD -L1 expression.Herein we aimed to evaluate the efficacy and safety of immunotherapy for the second and later line settings in metastatic NSCLC.
WoS Q Kategorisi
Q1Kaynak
Journal of Thoracic OncologyCilt
16Sayı
10Koleksiyonlar
- Bildiri Koleksiyonu [515]
- WoS İndeksli Yayınlar Koleksiyonu [6432]